首页> 外文期刊>The Journal of Nuclear Medicine >PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.
【24h】

PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.

机译:淋巴瘤中的PET / CT:增强型全剂量PET / CT与未增强型低剂量PET / CT的前瞻性研究。

获取原文
获取原文并翻译 | 示例
           

摘要

PET/CT combines functional and morphologic data and increases diagnostic accuracy in a variety of malignancies. This study prospectively compares the agreement between contrast-enhanced full-dose PET/CT and unenhanced low-dose PET/CT in lesion detection and initial staging of Hodgkin's disease and non-Hodgkin's lymphoma. METHODS: Forty-seven biopsy-proven lymphoma patients underwent a 18F-FDG PET/CT study that included unenhanced low-dose CT and enhanced full-dose CT for initial staging. Patients who had undergone previous diagnostic CT for initial staging were excluded. For every patient, each modality of PET/CT images was evaluated by either of 2 pairs of readers, with each pair comprising 1 experienced radiologist and 1 experienced nuclear physician. While evaluating one of the 2 types of PET/CT, the readers were unaware of the results of the other type. Lesion detection, number of sites affected in each anatomic region, and disease stage were assessed. Agreement between techniques was determined bythe kappa-statistic, and discordances were studied by the McNemar test. Clinical, analytic, histopathologic, diagnostic CT, and PET data; data from other imaging techniques; and follow-up data constituted the reference standard. RESULTS: For region-based analysis, no significant differences were found between unenhanced low-dose PET/CT and contrast-enhanced full-dose PET/CT, although full-dose PET/CT showed fewer indeterminate findings and a higher number of extranodal sites affected than did low-dose PET/CT. Agreement between the 2 types of PET/CT was almost perfect for disease stage (kappa = 0.92; P < 0.001). CONCLUSION: Our study showed a good correlation between unenhanced low-dose PET/CT and contrast-enhanced full-dose PET/CT for lymph node and extranodal disease in lymphomas, suggesting that unenhanced low-dose PET/CT might suffice in most patients as the only imaging technique for the initial staging of lymphomas, reserving diagnostic CT for selected cases.
机译:PET / CT结合了功能和形态学数据,并提高了各种恶性肿瘤的诊断准确性。这项研究前瞻性地比较了造影剂增强的全剂量PET / CT和未增强的低剂量PET / CT在病变检测以及霍奇金病和非霍奇金淋巴瘤的初始分期中的一致性。方法:47例经活检证实的淋巴瘤患者接受了18F-FDG PET / CT研究,包括未增强的低剂量CT和增强的全剂量CT进行初步分期。排除先前接受过诊断性CT初步分期的患者。对于每位患者,PET / CT图像的每种方式均由2对阅读器之一进行评估,每对包括1位经验丰富的放射科医生和1位经验丰富的核医师。在评估两种PET / CT类型之一时,读者并未意识到另一种类型的结果。评估病变检测,每个解剖区域受影响的部位数量以及疾病阶段。技术之间的一致性由kappa统计量确定,而不一致则由McNemar检验进行研究。临床,分析,组织病理学,诊断性CT和PET数据;其他成像技术的数据;随访数据构成参考标准。结果:对于基于区域的分析,未增强的低剂量PET / CT与对比增强的全剂量PET / CT之间没有发现显着差异,尽管全剂量PET / CT显示较少的不确定性发现和结外部位较多与低剂量PET / CT相比受影响。两种PET / CT之间的一致性对于疾病阶段几乎是完美的(kappa = 0.92; P <0.001)。结论:我们的研究表明,未增强的低剂量PET / CT与对比增强的全剂量PET / CT在淋巴瘤的淋巴结和结外疾病之间有良好的相关性,这表明,未增强的低剂量PET / CT在大多数患者中就足够了淋巴瘤初始分期的唯一成像技术,可为部分病例保留诊断性CT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号